Лечение рассеянного склероза у детей: обзор клинических исследований

Рассеянный склероз (РС) является редким нейровоспалительным и нейродегенеративным заболеванием, приводящим к инвалидизации и значительному снижению качества жизни. За последнее десятилетие исследования препаратов, изменяющих течение РС (ПИТРС), у взрослых значительно расширились в пользу применения высокоэффективных препаратов на ранних стадиях заболевания, а у педиатрических пациентов отдают предпочтение более безопасным, но менее эффективным ПИТРС.

Сегодня только два ПИТРС (финголимод и терифлуномид) были изучены в крупных исследованиях фазы III и одобрены регулирующими органами для использования у детей.

В последние годы всё большее число детей с РС получают высокоэффективную терапию такими препаратами, как натализумаб, моноклональные антитела к CD20, моноклональные антитела к CD52, а также аутологичную трансплантацию гемопоэтических стволовых клеток. Эти высокоэффективные методы лечения обеспечивают выраженное снижение воспалительной активности заболевания по сравнению с ПИТРС первой линии. Поэтому в настоящее время проводятся исследования фаз II и III, изучающие их эффективность и безопасность у детей с РС.

Данный описательный обзор посвящён базисному лечению РС у педиатрических пациентов, изучению характеристик эффективности и безопасности доступного в настоящее время арсенала лекарственных средств.

Участие авторов:
Абдуллаева Л.М. — концепция и дизайн, написание текста, редактирование;
Бурсагова Б.И. — написание текста, редактирование;
Куренков А.Л. — редактирование;
Кузенкова Л.М. — редактирование.
Все авторы — утверждение окончательного варианта статьи, ответственность за целостность всех частей статьи.

Финансирование. Исследование не имело спонсорской поддержки.

Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов.

Поступила 17.02.2023
Принята к печати 03.03.2023
Опубликована 20.04.2023

1. Belman A.L., Krupp L.B., Olsen C.S., Rose J.W., Aaen G., Benson L., et al. Characteristics of children and adolescents with multiple sclerosis. Pediatrics. 2016; 138(1): e20160120. https://doi.org/10.1542/peds.2016-0120

2. McGinley M., Rossman I.T. Bringing the HEET: the argument for high-efficacy early treatment for pediatriconset multiple sclerosis. Neurotherapeutics. 2017; 14(4): 985–98. https://doi.org/10.1007/s13311-017-0568-1

3. Brown J.W.L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., et al. Association of initial disease modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019; 321(2): 175–87. https://doi.org/10.1001/jama.2018.20588

4. Bevan C., Cree B.A. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol. 2014; 71(3): 269–70. https://doi.org/10.1001/jamaneurol.2013.5486

5. Chitnis T., Aaen G., Belman A., Benson L., Gorman M., Goyal M.S., et al. Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain. 2020; 143(9): 2733–41. https://doi.org/10.1093/brain/awaa199

6. Huppke P., Huppke B., Ellenberger D., Rostasy K., Hummel H., Stark W., et al. Therapy of highly active pediatric multiple sclerosis. Mult. Scler. J. 2019; 25(1): 72–8. https://doi.org/10.1177/1352458517732843

7. Yeh E.A., Weinstock-Guttman B., Ramanathan M., Ramasamy D.P., Willis L., Cox J.L., et al. Magnetic resonance imaging characteristics of children and adults with pediatric-onset multiple sclerosis. Brain. 2009; 132(Pt. 12): 3392–400. https://doi.org/10.1093/brain/awp278

8. Pfeifenbring S., Bunyan R.F., Metz I., Rover C., Huppke P., Gartner J., et al. Extensive acute axonal damage in pediatric multiple sclerosis lesions. Ann. Neurol. 2015; 77(4): 655–67. https://doi.org/10.1002/ana.24364

9. Kerbrat A., Aubert-Broche B., Fonov V., Narayanan S., Sled J.G., Arnold D.A., et al. Reduced head and brain size for age and disproportionately smaller thalami in child-onset MS. Neurology. 2012; 78(3): 194–201. https://doi.org/10.1212/WNL.0b013e318240799a

10. Amato M.P., Goretti B., Ghezzi A., Lori S., Zipoli V., Moiola L., et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 2010; 75(13): 1134–40. https://doi.org/0.1212/WNL.0b013e3181f4d821

11. Ruano L., Branco M., Portaccio E., Goretti B., Niccolai C., Patti F., et al. Patients with pediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: an Italian collaborative study. Mult. Scler. 2018; 24(9): 1234–4. https://doi.org/10.1177/1352458517717341

12. Gorman M.P., Healy B.C., Polgar-Turcsanyi M., Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch. Neurol. 2009; 66(1): 54–9. https://doi.org/10.1001/archneurol.2008.505

13. Food and Drug Association. Press Announcements – FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients. Office of the Commissioner; 2018. Available at: https://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm607501.htm

14. Paik J. Teriflunomide: Pediatric First Approval. Paediatr. Drugs. 2021; 23(6): 609–13. https://doi.org/10.1007/s40272-021-00471-1

15. Chitnis T., Banwell B., Kappos L., Arnold D.L., Gucuyener K., Deiva K., et al. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021; 20(12): 1001–11. https://doi.org/10.1016/S1474-4422(21)00364-1

16. Mikaeloff Y., Caridade G., Tardieu M., Suissa S. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur. J. Paediatr. Neurol. 2008; 12(3): 205–9. https://doi.org/10.1016/j.ejpn.2007.08.001

17. Mikaeloff Y., Moreau T., Debouverie M., Pelletier J., Lebrun C., Gout O., et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J. Pediatr. 2001; 139(3): 443–6. https://doi.org/10.1067/mpd.2001.117004

18. Tenembaum S.N., Segura M.J. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006; 67(3): 511–3. https://doi.org/10.1212/01.wnl.0000231137.24467.aa

19. Pohl D., Rostasy K., Gärtner J., Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005; 64(5): 888–90. https://doi.org/10.1212/01.WNL.0000153570.33845.6A

20. Pakdaman H., Fallah A., Sahraian M.A., Pakdaman R., Meysamie A. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics. 2006; 37(4): 257–60. https://doi.org/10.1055/s-2006-924723

21. Ghezzi A., Amato M.P., Capobianco M., Gallo P., Marrosu G., Martinelli V., et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult. Scler. 2005; 11(4): 420–4. https://doi.org/10.1191/1352458505ms1206oa

22. Tenembaum S.N., Banwell B., Pohl D., Krupp L.B., Boyko A., Meinel M., et al. Subcutaneous interferon beta-1a in pediatric multiple sclerosis: a retrospective study. J. Child Neurol. 2013; 28(7): 849–56. https://doi.org/10.1177/0883073813488828

23. Krysko K.M., Graves J., Rensel M., Weinstock-Guttman B., Aaen G., Benson L., et al. Use of newer disease modifying therapies in pediatric multiple sclerosis in the US. Neurology. 2018; 91(19): e1778–87. https://doi.org/10.1016/j.msard.2018.02.022

24. Jakimovski D., Kolb C., Ramanathan M., Zivadinov R., Weinstock-Guttman B. Interferon beta for multiple sclerosis. Cold Spring Harb. Perspect. Med. 2018; 8(11): a032003. https://doi.org/10.1101/cshperspect.a032003

25. Weinstock-Guttman B., Nair K.V., Glajch J.L., Ganguly T.C., Kantor D. Two decades of glatiramer acetate: from initial discovery to the current development of generics. J. Neurol. Sci. 2017; 376: 255–259. https://doi.org/10.1016/j.jns.2017.03.030

26. Banwell B., Reder A.T., Krupp L., Tenembaum S., Eraksoy M., Alexey B., et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006; 66(4): 472–6. https://doi.org/10.1212/01.wnl.0000198257.52512.1a

27. Ghezzi A., Amato M.P., Capobianco M., Gallo P., Marrosu M.G., Martinelli V., et al. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol. Sci. 2007; 28(3): 127–32. https://doi.org/10.1007/s10072-007-0804-2

28. Gartner J., Bruck W., Weddige A., Hummel H., Norenberg C., Bugge J.P., et al. Interferon beta-1b in treatment-naive paediatric patients with relapsing-remitting multiple sclerosis: Two-year results from the BETAPAEDIC study. Mult. Scler. J. Exp. Transl. Clin. 2017; 3(4): 2055217317747623. https://doi.org/10.1177/2055217317747623

29. Ghezzi A., Amato M.P., Annovazzi P., Capobianco M., Gallo P., La Mantia L., et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol. Sci. 2009; 30(3): 193–9. https://doi.org/10.1007/s10072-009-0083-1

30. Kornek B., Bernert G., Balassy C., Geldner J., Prayer D., Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics. 2003; 34(3): 120–6. https://doi.org/10.1055/s-2003-41274

31. Chitnis T., Tenembaum S., Banwell B., Krupp L., Pohl D., Rostasy K., et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult. Scler. 2012; 18(1): 116–27. https://doi.org/10.1177/1352458511430704

32. Ghezzi A., Banwell B., Boyko A., Amato M.P., Anlar B., Blinkenberg M., et al. The management of multiple sclerosis in children: a European view. Mult. Scler. 2010; 16(10): 1258–67. https://doi.org/10.1177/1352458510375568

33. Krysko K.M., Graves J., Rensel M., Weinstock-Guttman B., Aaen G., Benson L., et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology. 2018; 91(19): e1778–87. https://doi.org/10.1212/WNL.0000000000006471

34. Bar-Or A., Pachner A., Menguy-Vacheron F., Kaplan J., Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014; 74(6): 659–74. https://doi.org/10.1007/s40265-014-0212-x

35. Chitnis T., Tardieu M., Banwell B., Gücüyener K., Deiva K., Skripchenko N., et al. Evaluation of teriflunomide in children and adolescents with relapsing ms: terikids phase 3 study design, enrollment update, and baseline data (P4.354). Neurology. 2018; 90(15 Supplement): P4.354.

36. Chitnis T., Banwell B., Kappos L., Arnold D.L., Gucuyener K., Deiva K., et al. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021; 20(12): 1001–11. https://doi.org/10.1016/S1474-4422(21)00364-1

37. Ozel O., Vaughn C.B., Eckert S.P., Jakimovski D., Lizarraga A.A., Weinstock-Guttman B. Dimethyl Fumarate in the treatment of relapsing-remitting multiple sclerosis: patient reported outcomes and perspectives. Patient Relat. Outcome Meas. 2019; 10: 373–84. https://doi.org/10.2147/PROM.S168095

38. Alroughani R., Huppke P., Mazurkiewicz-Beldzinska M., Blaschek A., Valis M., Aaen G., et al. Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis. Front. Neurol. 2020; 11: 606418. https://doi.org/10.3389/fneur.2020.606418

39. Chitnis T., Arnold D.L., Banwell B., Bruck W., Ghezzi A., Giovannoni G., et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N. Engl. J. Med. 2018; 379(11): 1017–27. https://doi.org/10.1056/NEJMoa1800149

40. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010; 362(5): 402–15. https://doi.org/10.1517/14656566.2010.481671

41. Di Marco J. Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studies. Mult. Scler. 2012; 18(Suppl. 4): 55–227.

42. Gandhi S., Jakimovski D., Ahmed R., Hojnacki D., Kolb C., Weinstock-Guttman B., et al. Use of natalizumab in multiple sclerosis: current perspectives. Expert Opin. Biol. Ther. 2016; 16(9): 1151–62. https://doi.org/10.1080/14712598.2016.1213810

43. Ghezzi A., Moiola L., Pozzilli C., Brescia-Morra V., Gallo P., Grimaldi L.M., et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015; 15: 174. https://doi.org/10.1186/s12883-015-0433-y

44. Palavra F., Figueiroa S., Correia A.S., Tapadinhas F., Cerqueira J., Guerreiro R.P., et al. TyPed study: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal. Mult. Scler. Relat. Disord. 2021; 51: 102865. https://doi.org/10.1016/j.msard.2021.102865

45. Margoni M., Rinaldi F., Riccardi A., Franciotta S., Perini P., Gallo P. No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab. J. Neurol. 2020; 267(1): 100–5. https://doi.org/10.1007/s00415-019-09554-z

46. Kean J.M., Rao S., Wang M., Garcea R.L. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009; 5(3): e1000363. https://doi.org/10.1371/journal.ppat.1000363

47. Hauser S.L., Bar-Or A., Comi G., Giovannoni G., Hartung H.P., Hemmer B., et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 2017; 376(3): 221–34. https://doi.org/10.1056/NEJMoa1601277

48. Montalban X., Hauser S.L., Kappos L., Arnold D.L., Bar-Or A., Comi G., et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 2017; 376(3): 209–20. https://doi.org/10.1056/NEJMoa1606468

49. Bibinoğlu Amirov C., Saltık S., Yalçınkaya C., Tütüncü M., Saip S., Siva A., et al. Ocrelizumab in pediatric multiple sclerosis. Eur. J. Paediatr. Neurol. 2023; 43: 1–5. https://doi.org/10.1016/j.ejpn.2023.01.011

50. Jure Hunt D., Traboulsee A. Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic. Mult. Scler. J. Exp. Transl. Clin. 2020; 6(2): 2055217320926613. https://doi.org/10.1177/2055217320926613

51. Margoni M., Rinaldi F., Miante S., Franciotta S., Perini P., Gallo P. Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis. Mult. Scler. J. Exp. Transl. Clin. 2019; 5(3): 2055217319875471. https://doi.org/10.1177/2055217319875471

52. Burman J., Kirgizov K., Carlson K., Badoglio M., Mancardi G.L., De Luca G., et al. Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2017; 52(8): 1133–7. https://doi.org/10.1038/bmt.2017.40